Revenue combined USD 13.9 million of net product revenue from KOMZIFTI sales in the United States, following FDA approval in November 2025, and USD 8.9 million of collaboration revenue under the Kyowa license agreement. Collaboration revenue was USD 20.8 million in the prior-year quarter, …
Net income was USD 11,025 thousand against USD 2,087 thousand. After preferred dividends of USD 5,687 thousand and a gain of USD 777 thousand on the extinguishment of preferred stock,Net Incomeattributable to common stockholders was USD 6,115 thousand against a loss of USD 3,915 …
Cauchari-Olaroz ran at about 95% of design capacity, with cash operating costs near USD 5,800 per tonne and a cashOperating Marginof 67%. Year-to-date production of 28,490 tonnes keeps the operation on a path to the midpoint of its 35,000 to 40,000 tonne full-year guidance, …
Management said it is executing well on its priorities, which translated into favorable results including healthy EBITDA and another quarter of strong free cash flow generation. It said consolidated revenue reflects its wholly owned outpatient sites and its professional service segment, while system-wide outpatient …
For the nine months, revenue rose 4% to USD 44.1 million from USD 42.4 million, and the filing reportsNet Incomeof USD 35.1 million, against a net loss of USD 32.8 million a year earlier.
Peru and Colombia led growth with revenue increases of 45.1% and 45.7%, and Costa Rica revenue grew 4.2%, which management attributed to stronger market rents and the full stabilization of its facilities there. Management said it was the fourth consecutive quarter of 100% occupancy.
Management said the results of the quarter began to show the outcome of operational improvements, in the form of improved gross margins and growing demand. Net loss improved to USD 1.7 million, or USD 0.02 per basic and diluted share, from USD 2.9 million, …
Management said YUTREPIA has now delivered five consecutive quarters of growth in prescriptions, revenue and adjusted EBITDA. More than 60% of prescriptions since launch have included a pulmonary arterial hypertension diagnosis, rising above 70% in September. About 60% of prescribers have written for two …
Research and development expense was about USD 4.3 million against USD 2.9 million, and general and administrative expense was about USD 3.7 million against USD 2.3 million. Management said about USD 100,000 of deferredRevenueis anticipated to be recognized upon achievement of milestones.
General and administrative expenses were USD 12.7 million in the quarter, against USD 2.3 million in the third quarter of 2025. Cash, cash equivalents and marketable securities were USD 798.4 million at September 30.